Research at the Insitute for Medical Virology under the direction of Karin Moelling established various approaches for intervention against infectious diseases, cancer or Alzheimer’s disease. DBM Dahlem Biomed AG is a registered company founded by Karin Moelling (for contact see home). The profile of the company is presently consulting in Biotechnology, Biomedicine, Biology with focus on drug and vaccine design and developent, company profiles, clinical trials, reaching all the way from laboratory bench to patient bedside.
Karin Moelling welcomes requests from potential partners who are interested in working with her business ideas. If you are interested in discussing the possibility of a partnership please contact Karin Moelling. Please note that GMP material for project 2 is available for partnering.
Currently, five business ideas exist, which are described here.
- Gene silencing as antiviral and anticancer treatment -> Genesilencing
- Immune therapy against cancer by gene medicine -> Immune therapy
- Treatment of Age-related Macular Degeneration -> AMD
- New target against Diabetes -> Diabetes
- Therapy of Alzheimers Disease (AD) -> Alzheimer`s disease
Several patents owned by the Unitectra Zurich, the technology transfer organization of the University of Zurich, are filed or issued.
Most important papers for immediate reading
Matzen, K., Elzaouk, L., Matskevich A.A., Nitzsche, A., Heinrich, J. and Moelling, K. RNase H-mediated retrovirus destruction in vivo triggered by oligodeoxynucleotides. Nature Biotechnol. 25, 669-674 (2007). – Matzen 2007.pdf
Editorial Comment: Assisted suicide for retroviruses Nature Biotechnol. 25,643-644(2007)